Leaderboards/Schizophrenia research and treatment

Schizophrenia research and treatment

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

Insufficient data

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Iris Levy
Jerusalem Mental Health Center
99
2
Cosmin-Ioan Moga
Iuliu Hațieganu University of Medicine and Pharmacy
98
3
Holly B. Krasa
ActionAid
97
4
Ying Chen
Hainan Medical University
89
5
Huan Yu
Xijing Hospital
50
6
Hira Aslam
Unknown
47
7
Joshua Choma
University of Exeter
43
8
Tsung‐Ming Hu
Taipei Veterans General Hospital
36
9
Anna Di Maio
University of Campania "Luigi Vanvitelli"
7

Emerging Leaders Papers

1
National and State Societal Costs of Schizophrenia in the US in 2024
JAMA Psychiatry|2026
5 cit.
2
Global trends and health inequalities in mental disorders among older adults: a comprehensive analysis using global burden of disease 2021 data
Frontiers in Public Health|2025
4 cit.
3
Alternations of Plasma Fatty Acids in Patients With Bipolar Depression Under Acute Treatment of rTMS Combined With Quetiapine and Mood Stabilizer
Brain and Behavior|2025
3 cit.
4
Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study
The British Journal of Psychiatry|2025
3 cit.
5
Clinical practice guidelines for the treatment of borderline personality disorder: a systematic review of best practice in anticipation of MAiD MD-SUMC
Borderline Personality Disorder and Emotion Dysregulation|2025
2 cit.
6
Long-Acting Injectable Antipsychotic Use in Children and Adolescents in Comparison to Adults
Journal of Clinical Medicine|2025
2 cit.
7
Transcriptomic and proteomic analyses of SH-SY5Y neuroblastoma cells treated with amisulpride
Acta Neuropsychiatrica|2025
0 cit.
8
Clinical and Inflammatory Correlates of Negative Symptom Dimensions in Schizophrenia: Cross-Sectional Evidence for Neutrophil-to-Lymphocyte Ratio Associations With Motivational Deficits in Hospitalized Patients
Cureus|2025
0 cit.
9
Post-mortem brain analysis reveals altered monoaminergic system in the dorsolateral prefrontal cortex and hippocampus in chronic schizophrenia
Schizophrenia|2026
0 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Daniel M. Weinberger
Johns Hopkins University
87
2
Paul Stokes
King's College London
87
3
Junghee Lee
University of California, Los Angeles
86
4
Shekhar Saxena
World Health Organization
84
5
Oskar Hansson
Lund University
83
6
David Osborn
University College London
75
7
Muhammad Waqar
University of Bedfordshire
72
8
Robin Murray
Royal College of Surgeons in Ireland
70
9
Marc D. Binder
KU Leuven
66
10
Guy M. Goodwin
University of Oxford
65

All-Time Leaders Papers

1
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Schizophrenia Bulletin|2011
1.1k cit.
2
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Nature Communications|2017
927 cit.
3
Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas
World Psychiatry|2017
859 cit.
4
The dopamine theory of addiction: 40 years of highs and lows
Nature reviews. Neuroscience|2015
653 cit.
5
Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta‐analysis
Acta Psychiatrica Scandinavica|2013
643 cit.
6
Nonsocial and social cognition in schizophrenia: current evidence and future directions
World Psychiatry|2019
596 cit.
7
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Alzheimer s & Dementia|2022
568 cit.
8
Altering the course of schizophrenia: progress and perspectives
Nature Reviews Drug Discovery|2016
513 cit.
9
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
The British Journal of Psychiatry|2017
474 cit.
10
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Nature Aging|2023
443 cit.

Reagents for Schizophrenia research and treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

CELSR2 (D2M9H) Rabbit Monoclonal Antibody (BSA and Azide Free)

#19983$865
View Evidence →Cell Signaling Technology

Phospho-KAP-1 (Ser824) (F1Y6O) Rabbit Monoclonal Antibody

#77647$176
View Evidence →Cell Signaling Technology

Stat2 (D9J7L) Rabbit Monoclonal Antibody (InTraSeq™ 3' Conjugate 3093)

#84800$434
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Versican (F4U1K) Rabbit Monoclonal Antibody

#98586$161
View Evidence →Cell Signaling Technology

MO25 alpha/CAB39 (C49D8) Rabbit Monoclonal Antibody

#2716$158
View Evidence →Cell Signaling Technology

DYKDDDDK Tag (D6W5B) Rabbit Monoclonal Antibody (Binds to same epitope as Sigma-Aldrich Anti-FLAG M2 antibody) (mFluor™ Red 780 Conjugate)

#71323$465
View Evidence →